RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration

被引：1

作者：

Cherny, Nathan I. ^{[1
]}

Dafni, Urani ^{[2
,3
]}

Bogaerts, Jan ^{[4
]}

Latino, Nicola J. ^{[5
]}

Pentheroudakis, George ^{[6
]}

Douillard, Jean-Yves ^{[5
]}

Tabernero, Josep ^{[7
,8
]}

Zielinski, Christoph ^{[9
]}

Piccart, Martine J. ^{[10
]}

de Vries, Elisabeth G. E. ^{[11
]}

机构：

[1] Shaare Zedek Med Ctr, Dept Med Oncol, Canc Pain & Palliat Med Serv, IL-91031 Jerusalem, Israel

[2] Univ Athens, Lab Biostat, Sch Hlth Sci, Athens, Greece

[3] Frontier Sci Fdn Hellas, Athens, Greece

[4] EORTC Headquarters, Methodol Direct, Brussels, Belgium

[5] ESMO Head Off, Lugano, Switzerland

[6] Ioannina Univ Hosp, Med Oncol Dept, Ioannina, Greece

[7] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Med Oncol Dept, Barcelona, Spain

[8] Univ Autonoma Barcelona, Inst Oncol VHIO, Barcelona, Spain

[9] Med Univ Vienna, Div Oncol, Vienna, Austria

[10] Univ Libre Bruxelles, Jules Bordet Inst, Brussels, Belgium

[11] Univ Groningen, Dept Med Oncol, Univ Med Ctr Groningen, Groningen, Netherlands

来源：

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2018年 / 110卷 / 10期

关键词：

ESMO-MAGNITUDE; SCALE;

D O I：

10.1093/jnci/djy029

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：2

共 50 条

[1] RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration Response
Pierce, John P.
Leas, Eric C.
Benmarhnia, Tarik
Strong, David R.
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (10)
[2] Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration
Tibau, Ariadna
Molto, Consolacion
Ocana, Alberto
Templeton, Arnoud J.
Del Carpio, Luis P.
Del Paggio, Joseph C.
Barnadas, Agusti
Booth, Christopher M.
Amir, Eitan
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (05) : 486 - 492
[3] Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration
Molto, Consolacion
Hwang, Thomas J.
Borrell, Maria
Andres, Marta
Gich, Ignasi
Barnadas, Agusti
Amir, Eitan
Kesselheim, Aaron S.
Tibau, Ariadna
[J]. CANCER, 2020, 126 (19) : 4390 - 4399
[4] Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration Based on Single-Arm Trials
Tibau, Ariadna
Molto, Consolacion
Borrell, Maria
Del Paggio, Joseph C.
Barnadas, Agusti
Booth, Christopher M.
Amir, Eitan
[J]. JAMA ONCOLOGY, 2018, 4 (11) : 1610 - 1611
[5] Magnitude of clinical benefit of cancer drugs approved based on single-arm trials (SAT) by the US Food and Drug Administration (FDA)
Molto Valiente, C.
Borrell, M.
Ocana Fernandez, A.
Templeton, A. J.
del Carpio, L. P.
Del Paggio, J.
Barnadas, A.
Booth, C. M.
Tibau, A.
Amir, E.
[J]. ANNALS OF ONCOLOGY, 2018, 29 : 564 - 564
[6] Clinical benefit of breast cancer drugs approved by the United States Food and Drug Administration
Carlos Tapia, J.
Molto, Consolacion
Bujosa, Aida
Templeton, Arnoud J.
Barnadas, Agusti
Amir, Eithan
Tibau, Ariadna
[J]. CANCER RESEARCH, 2020, 80 (04)
[7] Clinical benefit of breakthrough cancer drugs approved by the United States Food and Drug Administration.
Molto, Consolacion
Hwang, Thomas J.
Andres, Marta
Borrell, Maria
Gich Saladich, Ignasi J.
Barnadas, Agust
Amir, Eitan
Kesselheim, Aaron S.
Tibau Martorell, Ariadna
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[8] Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration (vol 126, pg 4390, 2020)
Molto, Consolacion
Hwang, Thomas J.
Borrell, Maria
Andres, Marta
Gich, Ignasi
Barnadas, Agusti
Amir, Eitan
Kesselheim, Aaron S.
Tibau, Ariadna
[J]. CANCER, 2021, 127 (17) : 3266 - 3266
[9] Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
Liang, Fei
Zhang, Sheng
Wang, Qin
Li, Wenfeng
[J]. BMC CANCER, 2020, 20 (01)
[10] Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
Fei Liang
Sheng Zhang
Qin Wang
Wenfeng Li
[J]. BMC Cancer, 20

← 1 2 3 4 5 →